ABSTRACT
Purpose Premenopausal women diagnosed with estrogen receptor (ER) positive breast cancer are prescribed 5–10 years of endocrine therapy to prevent or delay recurrence. Many women who initiate endocrine therapy fail to complete the recommended course of treatment. In this study, we evaluated the association between early discontinuation of adjuvant endocrine therapy and breast cancer recurrence in a cohort of premenopausal women.
Patients and Methods We identified 4,503 premenopausal ER+ breast cancer patients who initiated adjuvant endocrine therapy and were registered in the Danish Breast Cancer Group clinical database (2002–2011). Women were excluded if they had a recurrence or were lost to follow-up less than 1.5 years after breast cancer surgery. Endocrine therapy was considered complete if the patient received at least 4.5 years of treatment or discontinued medication less than 6 months before recurrence. Exposure status was updated annually and modeled as a time-dependent variable. We accounted for baseline and time-varying confounders via time-varying weights, which we calculated from multivariable logistic regression models and included in regression models to estimate hazard ratios (HR) and accompanying 95% confidence intervals (CI) associating early discontinuation with breast cancer recurrence.
Results Over the course of follow-up, 1,001 (22%) women discontinued endocrine therapy. We observed 202 (20%) recurrences among those who discontinued endocrine therapy, and 388 (11%) among those who completed the recommended treatment. The multivariable-adjusted estimated rate of recurrence was higher in women who discontinued endocrine therapy relative to those who completed their treatment (HR=1.67, 95% CI 1.25, 2.14).
Conclusion These results highlight the importance of clinical follow-up and behavioral interventions that support persistence of adjuvant endocrine therapy to prevent breast cancer recurrence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported primarily by R01CA166825 from the US National Cancer Institute awarded to Timothy L. Lash and R167-2013-15861 from the Lundbeck Foundation awarded to Deirdre Cronin-Fenton. This work was also supported by NNF19OC0058710 from the Novo Nordisk Foundation awarded to Deirdre Cronin-Fenton. Lindsay J. Collin was supported by the US National Cancer Institute (F31CA239566). Thomas P. Ahern was supported in part by funding from the National Institute of General Medical Sciences (P20GM103644). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the US National Institutes of Health or other sources of funding support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Danish Data Protection Agency (record number KEA-2017-4), the Danish Medicines Agency, the DBCG (DBCG-2014-15), and the local Institutional Review Boards of the US co-investigators. This study is based on routinely collected registry data, so Danish law does not require an ethical board approval in Denmark, nor does it require patient consent to participate.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding support: This work was supported primarily by R01CA166825 from the US National Cancer Institute awarded to Timothy L. Lash and R167-2013-15861 from the Lundbeck Foundation awarded to Deirdre Cronin-Fenton. This work was also supported by NNF19OC0058710 from the Novo Nordisk Foundation awarded to Deirdre Cronin-Fenton. Lindsay J. Collin was supported by the US National Cancer Institute (F31CA239566). Thomas P. Ahern was supported in part by funding from the National Institute of General Medical Sciences (P20GM103644). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the US National Institutes of Health or other sources of funding support.
Conflicts of Interest: The authors have no conflicts of interest to declare.
Data Availability
Data are available within the paper. Individual level datasets are not publicly available in accordance with the Danish Act on Processing of Personal Data (https://www.datatilsynet.dk/english/the-act-on-processing-of-personal-data/read-the-act-on-processing-of-personal-data/compiled-version-of-the-act-on-processing-of-personal-data/). Interested researchers can contact the corresponding author for data requests.
